The effect of rapamycin on DNA synthesis in multiple tissues from late gestation fetal and postnatal rats

American Journal of Physiology - Cell Physiology

Volumn 295, Issue 2, 2008, Pages

  Sanders, Jennifer A ^a,b   Lakhani, Alisha ^a   Phornphutkul, Chanika ^a   Wu, Ke Ying ^a   Gruppuso, Philip A ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Growth; Mammalian target of rapamycin; Proliferation

Indexed keywords

DNA; PROTEIN S6; RAPAMYCIN; BROXURIDINE; IMMUNOSUPPRESSIVE AGENT; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; FETUS; GESTATIONAL AGE; HEART; INTESTINE; KIDNEY; LIVER CELL; LIVER REGENERATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL NUCLEUS; CELL PROLIFERATION; DNA REPLICATION; FETUS WEIGHT; LIVER; LIVER RESECTION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PRENATAL DEVELOPMENT; SPRAGUE DAWLEY RAT;

MAMMALIA; RATTUS;

ANIMALS; ANIMALS, NEWBORN; BROMODEOXYURIDINE; CELL NUCLEUS; CELL PROLIFERATION; DNA; DNA REPLICATION; FETAL WEIGHT; HEPATECTOMY; IMMUNOSUPPRESSIVE AGENTS; KI-67 ANTIGEN; LIVER; LIVER REGENERATION; PHOSPHORYLATION; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEIN S6; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 55949115012     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00450.2007     Document Type: Article

References (34)

1. Anand P, Boylan JM, Ou Y, Gruppuso PA. Insulin signaling during perinatal liver development in the rat. Am J Physiol Endocrinol Metab 283: E844-E852, 2002.
2. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004.
3. Boylan JM, Anand P, Gruppuso PA. Ribosomal protein S6 phosphorylation and function during late gestation liver development in the rat. J Biol Chem 276: 44457-44463, 2001.
4. Boylan JM, Gruppuso PA. Uncoupling of hepatic, epidermal growth factor-mediated mitogen-activated protein kinase activation in the fetal rat. J Biol Chem 273: 3784-3790, 1998.
5. Breslin EM, White PC, Shore AM, Clement M, Brennan P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br J Pharmacol 144: 791-800, 2005.
6. Chou MM, Masuda-Robens JM, Gupta ML. Cdc42 promotes G1 progression through p70 S6 kinase-mediated induction of cyclin E expression. J Biol Chem 278: 35241-35247, 2003.
7. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 31: 59-72, 1999.
8. Dilling MB, Germain GS, Dudkin L, Jayaraman AL, Zhang X, Harwood FC, Houghton PJ. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 277: 13907-13917, 2002.
9. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 253: 100-109, 1999.
10. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004.
11. Gaben AM, Saucier C, Bedin M, Barbu V, Mester J. Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts. Int J Cancer 108: 200-206, 2004.
12. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279: 2737-2746, 2004.
13. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273: 14424-14429, 1998.
14. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
15. Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence JC Jr, Houghton PJ. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 54: 815-824, 1998.
16. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat 4: 378-391, 2001.
17. Inoki K, Ouyang H, Li Y, Guan KL. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 69: 79-100, 2005.
18. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 16: 3693-3704, 1997.
19. Jiang YP, Ballou LM, Lin RZ. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver. J Biol Chem 276: 10943-10951, 2001.
20. Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 95: 955-960, 2006.
21. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 56: 47-60, 2005.
22. Luo Y, Marx SO, Kiyokawa H, Koff A, Massague J, Marks AR. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol 16: 6744-6751, 1996.
23. Marks AR. Rapamycin: signaling in vascular smooth muscle. Transplant Proc 35: 231S-233S, 2003.
24. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720, 1996.
25. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24: 3112-3124, 2004.
26. Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, Dor Y, Zisman P, Meyuhas O. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 19: 2199-2211, 2005.
27. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31: 335-340, 1998.
28. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35: 7S-14S, 2003.
29. Shapira M, Kakiashvili E, Rosenberg T, Hershko DD. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res 8: R46, 2006.
30. Singha UK, Jiang Y, Yu S, Luo M, Lu Y, Zhang J, Xiao G. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem 103: 434-446, 2008.
31. Steer CJ. Liver regeneration. FASEB J 9: 1396-1409, 1995.
32. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058, 2005.
33. Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 83: 1114-1121, 2007.
34. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66: 6589-6597, 2006.